Related Experiment Video
Updated: Jul 2, 2025

Measuring Composition of CD95 Death-Inducing Signaling Complex and Processing of Procaspase-8 in this Complex
Published on: August 2, 2021
IRE1 RNase controls CD95-mediated cell death
Diana Pelizzari-Raymundo1,2, Victoria Maltret1,2, Manon Nivet1,2
1Inserm U1242, University of Rennes, Rennes, France.
Abstract:
Signalling by the Unfolded Protein Response (UPR) or by the Death Receptors (DR) are frequently activated towards pro-tumoral outputs in cancer. Herein, we demonstrate that the UPR sensor IRE1 controls the expression of the DR CD95/Fas, and its cell death-inducing ability. Both genetic and pharmacologic blunting of IRE1 activity increased CD95 expression and exacerbated CD95L-induced cell death in glioblastoma (GB) and Triple-Negative Breast Cancer (TNBC) cell lines. In accordance, CD95 mRNA was identified as a target of Regulated IRE1-Dependent Decay of RNA (RIDD). Whilst CD95 expression is elevated in TNBC and GB human tumours exhibiting low RIDD activity, it is surprisingly lower in XBP1s-low human tumour samples. We show that IRE1 RNase inhibition limited CD95 expression and reduced CD95-mediated hepatic toxicity in mice. In addition, overexpression of XBP1s increased CD95 expression and sensitized GB and TNBC cells to CD95L-induced cell death. Overall, these results demonstrate the tight IRE1-mediated control of CD95-dependent cell death in a dual manner through both RIDD and XBP1s, and they identify a novel link between IRE1 and CD95 signalling.
Insights
The unfolded protein response sensor IRE1 regulates CD95/Fas death receptor expression and function in cancer. Inhibiting IRE1 enhances CD95-mediated cell death in glioblastoma and triple-negative breast cancer.
Area of Science:
- Cancer Biology
- Molecular Cell Biology
- Signaling Pathways
Background:
- Unfolded Protein Response (UPR) and Death Receptor (DR) signaling are often co-opted for tumor progression.
- IRE1 is a key sensor of the UPR, implicated in cancer cell survival and proliferation.
Purpose of the Study:
- To investigate the regulatory role of IRE1 in controlling Death Receptor CD95/Fas expression and function.
- To explore the therapeutic potential of targeting the IRE1-CD95 axis in glioblastoma and triple-negative breast cancer.
Main Methods:
- Genetic and pharmacologic inhibition of IRE1 activity.
- Analysis of CD95 mRNA expression and its regulation by Regulated IRE1-Dependent Decay of RNA (RIDD).
- Assessment of CD95L-induced cell death in cancer cell lines and in vivo mouse models.
Main Results:
- IRE1 inhibition increased CD95 expression and sensitized glioblastoma and triple-negative breast cancer cells to CD95L-induced death.
- CD95 mRNA is a target of IRE1-mediated RIDD.
- IRE1 inhibition reduced CD95-mediated hepatic toxicity in mice.
- XBP1s overexpression increased CD95 expression and cell death sensitivity.
Conclusions:
- IRE1 exerts dual control over CD95-dependent cell death via RIDD and XBP1s.
- This study reveals a novel regulatory link between IRE1 and CD95 signaling in cancer.
- Targeting IRE1 may offer a therapeutic strategy to enhance CD95-mediated anti-tumor immunity.
Related Concept Videos
Regulation of the Unfolded Protein Response
The Extrinsic Apoptotic Pathway
Caspases
Experimental RNAi
The Intrinsic Apoptotic Pathway
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

